DYNAVAX TECHNOLOGIES
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
DYNAVAX TECHNOLOGIES
Social Links:
Industry:
Biopharma Biotechnology Clinical Trials Health Care Medical Device
Founded:
1996-01-01
Address:
Berkeley, California, United States
Country:
United States
Website Url:
http://www.dynavax.com
Total Employee:
501+
Status:
Active
Contact:
+1 510 848 1327
Email Addresses:
[email protected]
Total Funding:
1.04 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Universal Analytics Domain Not Resolving Apache Microsoft Exchange Online
Similar Organizations
Vero Biotech
Vero Biotech is a biopharmaceutical company that commercializes inhaled nitric oxide delivery systems for healthcare providers.
Inventiva Pharma
Inventiva is a biopharmaceutical company with several drug candidates at clinical and preclinical stage.
Aptose Biosciences
Aptose Biosciences is a biopharmaceutical company focused on the discovery, research and development of novel, first-in-class
TrioMed Innovations
TrioMed Innovations develops antimicrobial technologies and products to prevent the spreading of infections and diseases.
Vygon
Vygon offer health professionals efficient and innovative single-use medical products adapted to their needs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2009-11-10 | Symphony Dynamo | Symphony Dynamo acquired by Dynavax Technologies | N/A |
Investors List
Coalition for Epidemic Preparedness Innovations
Coalition for Epidemic Preparedness Innovations investment in Post-IPO Debt - Dynavax Technologies
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Grant - Dynavax Technologies
CRG
CRG investment in Post-IPO Debt - Dynavax Technologies
Hercules Capital
Hercules Capital investment in Debt Financing - Dynavax Technologies
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases investment in Grant - Dynavax Technologies
Deerfield
Deerfield investment in Post-IPO Debt - Dynavax Technologies
Alta Partners
Alta Partners investment in Series D - Dynavax Technologies
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series D - Dynavax Technologies
Care Capital
Care Capital investment in Series D - Dynavax Technologies
Forward Ventures
Forward Ventures investment in Series D - Dynavax Technologies
Key Employee Changes
| Date | New article |
|---|---|
| 2020-09-24 | Dynavax Announces Appointment of New Board Member and Planned Retirement of Chief Financial Officer |
Official Site Inspections
http://www.dynavax.com Semrush global rank: 2.14 M Semrush visits lastest month: 9.43 K
- Host name: ec2-34-192-255-123.compute-1.amazonaws.com
- IP address: 34.192.255.123
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Dynavax Technologies"
Dynavax Technologies | Toll-like Receptor | Vaccines
May 1, 2025 Dynavax Technologies is focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.See details»
Dynavax Technologies - Crunchbase Company Profile & Funding
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine …See details»
Dynavax Technologies - LinkedIn
Dynavax Technologies | 15,974 followers on LinkedIn. Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against ...See details»
Investor Relations | Dynavax Technologies Corporation
Mar 4, 2025 Dynavax is a commercial-stage biopharmaceutical company built on the foundation of our significant experience and expertise in vaccine development and commercialization. …See details»
Careers at Dynavax Technologies
Dynavax is dedicated to developing and commercializing innovative vaccines to help protect the world against infectious diseases. We are a dynamic team with diverse backgrounds, …See details»
Dynavax Technologies - Org Chart, Teams, Culture & Jobs - The Org
View Dynavax Technologies' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Dynavax to Participate in Upcoming Investor Conferences
Feb 25, 2025 For more information about our marketed products and development pipeline, visit www.dynavax.com. For Investors/Media: Paul Cox [email protected] 510-665-0499. Nicole …See details»
Dynavax Appoints Ryan Spencer as Chief Executive Officer and
Dec 16, 2019 Mr. Novack joined Dynavax in 2013, and has led the company’s technical operations, supply chain, and quality teams through FDA approval, launch, and …See details»
Working at Dynavax - Great Place To Work®
Dynavax has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all …See details»
Press Releases - Dynavax Technologies Corporation
Apr 29, 2025 Dynavax's Board is Overseeing Record Operational and Financial Performance Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution …See details»
Dynavax's Evolving Business Model - lifescienceleader.com
Feb 9, 2024 Dynavax’s two-dose scheduling benefit versus competing hepatitis B vaccines has helped grow Heplisav-B’s market share to over 40% by the end of 2023, per Spencer. …See details»
Dynavax Technologies - Craft
The Company develops immunotherapies based on cutting-edge Toll-Like Receptor biology and its ability to modulate the immune system.Dynavax Technologies Corporation's clinical-stage …See details»
Dynavax - amga.org
If you are an organization that provides healthcare, you can join AMGA as a member. Learn More. Corporate Partnership. If you are an organization that supports healthcare provider …See details»
Job Opportunities at Dynavax Technologies
We are a values-based organization that looks out for our employees and fosters a rewarding work environment. We welcome you to join our team! Job search filters. ... Dynavax is an …See details»
/C O R R E C T I O N -- Dynavax Technologies/ - Yahoo Finance
4 days ago Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative …See details»
Dynavax Highlights Superior Board Leadership Overseeing Long
Apr 30, 2025 Since Dynavax's pivot, our Board has overseen a disciplined strategy that is generating superior value: Total stockholder returns of 267% over the past five years: Far …See details»
Dynavax Responds to Deep Track and Highlights Long-Term Value …
Feb 19, 2025 Reiterates Meaningful Board Change Already Underway. EMERYVILLE, Calif., Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) …See details»
Dynavax Issues Statement and Mails Letter to Stockholders …
4 days ago The current Dynavax Board, including, our nominees up for re-election this year— Brent MacGregor, Scott Myers (our Chairman), Lauren Silvernail and Elaine Sun — are …See details»
Benefits | Dynavax Technologies
Dynavax is proud to offer comprehensive and highly competitive benefits to our U.S. based employees and their families. Medical Insurance We provide multiple medical plan options to …See details»
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
3 days ago Dynavax Technologies (DVAX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward …See details»